tiprankstipranks
Advertisement
Advertisement

NURPF Stock Latest News

Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
Company AnnouncementsNeuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
11d ago
Neuren Investors Back Board and CEO Options but Reject Constitution Changes
PremiumCompany Announcements
Neuren Investors Back Board and CEO Options but Reject Constitution Changes
16d ago
Neuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders
PremiumCompany Announcements
Neuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders
17d ago
Neuren Advances NNZ-2591 Into Phase 3 Extension, Deepening Its Rare-Disease Pipeline
PremiumCompany Announcements
Neuren Advances NNZ-2591 Into Phase 3 Extension, Deepening Its Rare-Disease Pipeline
21d ago
NURPF
Neuren launches Investor Hub to bolster engagement as neurological pipeline advances
PremiumCompany Announcements
Neuren launches Investor Hub to bolster engagement as neurological pipeline advances
1M ago
Neuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity
PremiumCompany AnnouncementsNeuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity
1M ago
Neuren Rides 20% DAYBUE Sales Growth and Strong STIX Launch in Q1 2026
Premium
Company Announcements
Neuren Rides 20% DAYBUE Sales Growth and Strong STIX Launch in Q1 2026
1M ago
Neuren Updates Market on Ongoing On-Market Share Buy-Back
Premium
Company Announcements
Neuren Updates Market on Ongoing On-Market Share Buy-Back
1M ago
Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting
PremiumCompany Announcements
Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting
2M ago
Neuren Sets Hybrid 2026 AGM, Puts Director Re-election to Shareholder Vote
PremiumCompany Announcements
Neuren Sets Hybrid 2026 AGM, Puts Director Re-election to Shareholder Vote
2M ago
Neuren Files Updated ASX Governance Appendix, Confirms Compliance With Key Standards
PremiumCompany Announcements
Neuren Files Updated ASX Governance Appendix, Confirms Compliance With Key Standards
2M ago
Neuren details 2025 progress and governance in latest annual report
PremiumCompany Announcements
Neuren details 2025 progress and governance in latest annual report
2M ago
Neuren Updates Market on Ongoing On‑Market Share Buy‑Back
PremiumCompany AnnouncementsNeuren Updates Market on Ongoing On‑Market Share Buy‑Back
2M ago
Neuren Pharmaceuticals Updates Market on Ongoing Share Buy-Back
Premium
Company Announcements
Neuren Pharmaceuticals Updates Market on Ongoing Share Buy-Back
2M ago
Neuren Updates Market on Progress of On-Market Share Buy-Back
Premium
Company Announcements
Neuren Updates Market on Progress of On-Market Share Buy-Back
2M ago
Neuren Cancels Shares Following On-Market Buy-Back
PremiumCompany Announcements
Neuren Cancels Shares Following On-Market Buy-Back
2M ago
Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
PremiumCompany Announcements
Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
2M ago
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
PremiumCompany Announcements
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
3M ago
Neuren updates market on ongoing on‑market share buy‑back
PremiumCompany Announcements
Neuren updates market on ongoing on‑market share buy‑back
3M ago
Neuren Updates Market on Ongoing On-Market Share Buy-Back
PremiumCompany AnnouncementsNeuren Updates Market on Ongoing On-Market Share Buy-Back
3M ago
Neuren director Joseph Basile lifts stake with on-market share purchase
Premium
Company Announcements
Neuren director Joseph Basile lifts stake with on-market share purchase
3M ago
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
Premium
Company Announcements
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >